Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

Alexion gets Japanese rights to BridgeBio's ATTR therapy
The Eidos Therapeutics Inc. (NASDAQ:EIDX) subsidiary of BridgeBio Pharma Inc. (NASDAQ:BBIO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) exclusive rights to develop and commercialize transthyretin-mediated amyloidosis (ATTR)

Read the full 320 word article

User Sign In